A detailed history of Susquehanna International Group, LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 674,119 shares of ACAD stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
674,119
Previous 329,568 104.55%
Holding current value
$11.5 Million
Previous $5.36 Million 93.73%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.14 - $19.14 $5.22 Million - $6.59 Million
344,551 Added 104.55%
674,119 $10.4 Million
Q2 2024

Aug 15, 2024

BUY
$14.62 - $18.42 $2.29 Million - $2.88 Million
156,465 Added 90.39%
329,568 $5.36 Million
Q1 2024

May 07, 2024

SELL
$17.79 - $30.86 $3.6 Million - $6.24 Million
-202,160 Reduced 53.87%
173,103 $3.2 Million
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $1.1 Million - $1.68 Million
52,883 Added 16.4%
375,263 $11.7 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $5.5 Million - $8.83 Million
263,917 Added 451.43%
322,380 $6.72 Million
Q2 2023

Aug 11, 2023

SELL
$17.8 - $25.65 $3.06 Million - $4.41 Million
-171,797 Reduced 74.61%
58,463 $1.4 Million
Q1 2023

May 16, 2023

BUY
$16.32 - $20.92 $2.47 Million - $3.17 Million
151,522 Added 192.44%
230,260 $4.33 Million
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $1.6 Million - $2.1 Million
-112,852 Reduced 58.9%
78,738 $1.25 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $65,992 - $85,448
4,677 Added 2.5%
191,590 $3.13 Million
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $981,344 - $2.05 Million
75,430 Added 67.66%
186,913 $2.63 Million
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $5.88 Million - $7.72 Million
-280,637 Reduced 71.57%
111,483 $2.7 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $1.31 Million - $2.12 Million
78,180 Added 24.9%
392,120 $9.15 Million
Q3 2021

Nov 15, 2021

SELL
$15.78 - $24.77 $3.44 Million - $5.4 Million
-218,034 Reduced 40.99%
313,940 $5.22 Million
Q2 2021

Aug 11, 2021

BUY
$19.4 - $27.42 $5.63 Million - $7.96 Million
290,358 Added 120.17%
531,974 $13 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $1.83 Million - $4.01 Million
72,997 Added 43.29%
241,616 $6.23 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $2.19 Million - $3.03 Million
-53,303 Reduced 24.02%
168,619 $9.01 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $2.35 Million - $3.68 Million
64,549 Added 41.02%
221,922 $9.15 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $3.22 Million - $4.32 Million
81,940 Added 108.63%
157,373 $7.63 Million
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $7.19 Million - $10.6 Million
-227,086 Reduced 75.07%
75,433 $3.19 Million
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $1.56 Million - $2.22 Million
43,147 Added 16.64%
302,519 $12.9 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $1.53 Million - $3.02 Million
68,670 Added 36.01%
259,372 $9.34 Million
Q2 2019

Aug 16, 2019

BUY
$23.32 - $28.12 $309,339 - $373,011
13,265 Added 7.48%
190,702 $5.1 Million
Q2 2019

Aug 14, 2019

BUY
$23.32 - $28.12 $2.9 Million - $3.5 Million
124,342 Added 234.19%
177,437 $4.74 Million
Q1 2019

May 15, 2019

SELL
$16.17 - $27.38 $1.2 Million - $2.03 Million
-74,013 Reduced 58.23%
53,095 $1.43 Million
Q4 2018

Feb 14, 2019

SELL
$14.32 - $22.92 $1.97 Million - $3.16 Million
-137,692 Reduced 52.0%
127,108 $2.06 Million
Q1 2018

May 15, 2018

SELL
$22.47 - $32.33 $3.28 Million - $4.72 Million
-145,986 Reduced 35.54%
264,800 $5.95 Million
Q4 2017

Feb 14, 2018

SELL
$26.84 - $39.14 $2.58 Million - $3.76 Million
-96,151 Reduced 18.97%
410,786 $12.4 Million
Q3 2017

Nov 20, 2017

BUY
$29.49 - $38.37 $14.9 Million - $19.5 Million
506,937
506,937 $19.1 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.